Click to join the Growin investment community!

Inmode ltd.INMD.US Overview

US StockHealthcare
(No presentation for INMD)

INMD Overall Performance

METRIC
VALUE
vs. INDUSTRY
EPS
2.57
PE Ratio
5.29
Forward PE
7.29
PS Ratio
2.59
PB Ratio
1.50
Price-to-FCF
9.99
Gross Margin
79.98%
Net Margin
44.50%
Revenue Growth (YoY)
-3.62%
Profit Growth (YoY)
-6.29%
3-Year Revenue Growth
-5.57%
3-Year Profit Growth
-6.85%

INMD AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

INMD Current Performance

0.13%

Inmode ltd.

-0.47%

Avg of Sector

-0.64%

S&P500

INMD Key Information

INMD Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2025Q1
2025Q2
2025Q3
2025Q4
2026Q1

INMD Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2024Q4
2024Q3
2024Q2
2024Q1

INMD Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.

Price of INMD

INMD FAQ

  • When is INMD's latest earnings report released?

    The most recent financial report for Inmode ltd. (INMD) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating INMD's short-term business performance and financial health. For the latest updates on INMD's earnings releases, visit this page regularly.

  • Where does INMD fall in the P/E River chart?

    According to historical valuation range analysis, Inmode ltd. (INMD)'s current price-to-earnings (P/E) ratio is 4.92, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of INMD?

    According to the latest financial report, Inmode ltd. (INMD) reported an Operating Profit of 22.88M with an Operating Margin of 23.93% this period, representing a growth of 24.94% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is INMD's revenue growth?

    In the latest financial report, Inmode ltd. (INMD) announced revenue of 95.6M, with a Year-Over-Year growth rate of 10.59%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does INMD have?

    At the end of the period, Inmode ltd. (INMD) held Total Cash and Cash Equivalents of 216.24M, accounting for 0.31 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does INMD go with three margins increasing?

    In the latest report, Inmode ltd. (INMD) achieved the “three margins increasing” benchmark, with a gross margin of 80%%, operating margin of 23.93%%, and net margin of 28%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess INMD's profit trajectory and future growth potential.

  • Is INMD's EPS continuing to grow?

    According to the past four quarterly reports, Inmode ltd. (INMD)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.42. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of INMD?

    Inmode ltd. (INMD)'s Free Cash Flow (FCF) for the period is 23.85M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 42.95% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of INMD?

    The latest valuation data shows Inmode ltd. (INMD) has a Price-To-Earnings (PE) ratio of 4.92 and a Price/Earnings-To-Growth (PEG) ratio of 0.14. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.